bullish
SK Bioscience (302440 KS): Core Vaccines Gaining Traction; COVID Vaccine Gets International Approval
279 Views13 Jun 2023 18:37
SUMMARY
- SK Bioscience (302440 KS) recorded 5% YoY growth in core vaccine revenue to KRW17B in 1Q23, mainly driven by shingles vaccine, SKY Zoster due to its continued market leadership.
- In May 2023, SK Bioscience received marketing authorization of its COVID-19 vaccine, SKYCovion from the UK MHRA. SKYCovion became the eighth COVID-19 vaccine approved in the UK.
- SK Bioscience targets revenue of KRW220 billion by 2024 mainly through global expansion of existing in-house vaccines and expanding its contract manufacturing business.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- SK Bioscience (302440 KS): Significantly Improved 3Q Result Benefitted From One-Time Payment28 Oct 2023
- SK Bioscience (302440 KS): Flu Vaccine Output Resumes; Next-Gen Typhoid Vaccine Is On Card14 Sep 2023
- SK Bioscience (302440 KS): Core Vaccines Gaining Traction; COVID Vaccine Gets International Approval13 Jun 2023
- SK Bioscience (302440 KS): Disappointing 2022 Result; Non-COVID Vaccines Are Key to Revival05 Mar 2023
- SK Bioscience (302440 KS): Murky Outlook On Weak Vaccine Demand And Flooding Supply06 Sep 2022
- SK Bioscience (302440 KS): An Attractive Pure-Play on Vaccines- Both COVID and Non-COVID13 Mar 2022
x